Collate

A startup barely a year past its first customer just raised a reported $95 million at a valuation knocking on $1 billion. Collate's pitch is an AI platform that drafts the regulated paperwork standing between life-sciences companies and their drug and device approvals. The pedigree underneath it checks out: CEO Surbhi Sarna's previous company was acquired by Boston Scientific in a deal the press reported in full. What the company's own narrative carries, though — roughly fifty customers, accuracy in the mid-90s on regulated documents — has no outside-the-room proof behind it yet. We ran 21 public sources through five independent partner lenses in a single day, every claim cited and no founder spin in the mix. The valuation rests on whether this is durable software or a polished services overlay, and that turns on proof the public record does not hold. The teardown brings back what the round is actually priced on. Read it before the next markup locks the price in.